Pure Extracts: Study on First Psilocybin Products Initiated – Columns

Exciting news just before the end of the year from Pure Extracts Technologies (CSE PULL / WKN A2QJAJ): The extraction company, which is already active in the cannabis sector and is already pushing into the market for functional mushroom products, is continuing to prepare for entry into the psychedelics sector. In cooperation with the Toronto Institute of Pharmaceutical Technology (TIPT) and under the direction of the renowned expert Dr. Alexander MacGregor, a first, corresponding study was initiated!

Pure Extracts researches the formulation and manufacture of oral tablets, capsules and a psilocybin-based nasal gel, the psychoactive component of so-called “magic mushrooms”, for active treatment. This study will focus on the formulation, manufacture and clinical bioavailability testing of fast-acting psilocybin dosage forms. The study also examines the manufacture, packaging and labeling of clinical batches, as well as conformity and stability tests (including long-term tests and accelerated tests).

As Pure Extracts further stated, the study will meet the standards of both Canadian Good Manufacturing Practice (“GMP”) and Good Clinical Practice (“GCP”). Ben Nikolaevsky, CEO of the company, reiterated the “invaluable value” of the support from TIPT, one of Canada’s leading research and development organizations in the pharmaceutical sector. They are delighted to be laying the foundations for entry into the controlled substances sector of psychedelics with the help of the experts, said the Pure Extracts CEO.

While the company is still waiting to receive a so-called Dealer’s License, which among other things enables the trade in and distribution of psilocybin, the Toronto Institute of Pharmaceutical Technology has a Health Canada Drug Establishment License, Cannabis Drug License and Dealer’s License and is therefore licensed to own psychedelic drug compounds. At Dr. MacGregor is a pioneer in pharmaceutical science and an expert in pharmaceutical technology and novel drug delivery systems. He developed several worldwide patents in the field of medical treatment and drug delivery technologies.

For us, today’s news is an indication that Pure Extracts Technologies (CSE PULL / WKN A2QJAJ) is preparing the step into the “hot” psychedelics market quickly but also systematically and prudently. We are definitely looking forward to the new year, when these and other initiatives bear their first fruits – and will continue to report on what we believe to be risky but also very promising company.

Subscribe to our free newsletter:
Visit us on Twitter:

Risk warning: GOLDINVEST Consulting GmbH offers editors, agencies and companies the opportunity to post comments, analyzes and messages to publish. This content is intended solely for the information of the reader and does not represent any kind of call for action, neither explicitly nor implicitly are they to be understood as a guarantee of possible price developments. Furthermore, they are in no way a substitute for individual, expert investment advice, rather they are advertising / journalistic texts. Readers who make investment decisions or carry out transactions on the basis of the information provided here act entirely at their own risk. The acquisition of securities involves high risks, which can lead to the total loss of the capital invested. GOLDINVEST Consulting GmbH and its authors expressly exclude any liability for financial losses or the content-related guarantee for topicality, correctness, appropriateness and completeness of the articles offered here. Please take note of our Terms of Use.

In accordance with Section 34b WpHG and Section 48f Paragraph 5 BörseG (Austria), we would like to point out that partners, authors and / or employees of GOLDINVEST Consulting GmbH can hold shares in Pure Extracts Technologies and thus a conflict of interest could exist. Furthermore, we cannot rule out that other stock market letters, media or research firms will discuss the values ​​we have discussed during the same period. Therefore, symmetrical generation of information and opinions can occur during this period. Furthermore, there is a consulting or other service contract between GOLDINVEST Consulting GmbH and a third party in the issuer’s warehouse (Pure Extracts Technologies), which creates a conflict of interest, especially since this third party grants GOLDINVEST Consulting GmbH for a fee for reporting Pure Extracts Technologies rewards. This third party may also hold, sell or buy shares in the issuer and would benefit from an increase in the price of Pure Extracts Technologies shares. This is another conflict of interest.

PERSONAL-FINANCIAL.COM publishes analyzes, columns and news from various sources in this section.
PERSONAL-FINANCIAL.COM AG is not responsible for content that is recognizable by third parties in the “News” area
This website has been discontinued and does not adopt it as its own. These contents are in particular through
a corresponding “from” mark below the article heading and / or through the link
“To read the full article, please click here.” responsible for
this content is solely the named third party.


Related Articles

Back to top button